| Tomah physician assistant’s play tells story behind breast cancer
Nancy Heerens-Knudson says she is a paranoid health-care provider.When the physician assistant suspects breast cancer in a patient, Heerens-Knudson will make sure she goes the distance to find it or rule it out.
"If there is a lump, I'll want to look at it again and again," she said. "I think too many doctors tend to pass it off as nothing, but I'm very extra careful for good reasons."At age 58, Heerens-Knudson is a 22-year breast cancer survivor. She believes physicians should give women a breast exam every time they are seen."The breast check should be a routine check," she said. "Women should insist on it."She dishes out warnings to patients and physicians alike. "The No. 1 most grievous error that medical folks make is to minimize someone's concern about a breast lump," Heerens-Knudson said.
Archives: October 2006
Criticizing Vonage feels like kicking a dog. Yet, what else am I supposed to do looking at the Web-calling outfit's third-quarter results? The company's churn is up, customer acquisition costs are up, lifetime value per supbscriber is down. That's very troubling. Google Gobbles JotSpot Posted by: Rob Hof on October 31, Categories: Google, Power of Us, Silicon Valley, Web 2.0, Wiki, software as service, startups Search giant Google has bought yet another hot startup that had hoped to be one of the next big things (and no doubt still does). JotSpot, the company started three... Oracle Drops the Bomb on Red Hat Posted by: Steve Hamm on October 25, Categories: open source software Red Hat's stock took a pounding earlier this year when Oracle CEO Larry Ellison suggested that he might buy a Linux company and compete with the No.
Long-awaited blueprints to guide cancer survivors' future care
A new push is on to provide patients with "survivor plans," long-awaited blueprints for the customized follow-up care they'll require for years. Few today get that careful send-off as they leave cancer specialists and head back to their regular doctors, even though the Institute of Medicine alerted the nation two years ago that these survivors' special needs weren't being met. .
Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical ...
BETHESDA, Md., Oct. 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (NASDAQ: MITI) , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for the treatment of cancer, inflammatory and autoimmune diseases, announced today that the Paul-Ehrlich Institute has approved an Investigational Medicinal Product Dossier (IMPD) for the conduct of a phase 2 clinical trial testing MT103 in patients with acute lymphoblastic leukemia (ALL) in Germany. MT103, a BiTE(R) antibody targeting the CD19 antigen, which is expressed on most malignant B lymphoma cells, is also being evaluated in an ongoing phase 1 clinical trial in Europe in non- Hodgkin's lymphoma (NHL). Micromet and MedImmune, a subsidiary of AstraZeneca plc, are currently developing MT103 (also known as MEDI-538).
|
